Drawing for CYTOO

USPTO serial 79443404

CYTOO

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
BARRESE, TAYLOR ANN
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with CYTOO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Steven J. Solomon

Steven J. Solomon Tucker Ellis LLP950 Main Avenue, Suite 1100Cleveland, OH 44113United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; Veterinary products, namely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; Sanitary products for medicine, namely sanitary preparations for medical use; Chemical and biological preparations for medical use, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity , diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseasesACTIVE—
009Quality control and testing devices namely culture plates to test and conduct quality control in the field of biology, biotechnology and pharmacy; downloadable software for the collection, processing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instruments, namely computer hardware and downloadable software for data analysis, database management, data processing, in the field of life science research and the pharmaceutical industry market and diagnosticsACTIVE—
042Medical, biotechnological, and pharmaceutical research; research and development of chemical, biological and scientific products and materials in the biological, biotechnological, medical, diagnostic and pharmaceutical fields; scientific research, advisory and information services in the medical, biotechnological, pharmaceutical, diagnostic, technological and industrial fields; design and development of computers, software and computer platforms; technical testing namely technological testing in the scientific, biological, biotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testing, technical testing namely, technological testing in the scientific, biological, biotechnological and medical fields and scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imaging, in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; diagnostic and industrial research in the biological, biotechnological and medical fieldsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 17, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 11, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 20, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 20, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 20, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Oct 20, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 20, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 12, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 12, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 12, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 14, 2026RFNTREFUSAL PROCESSED BY IB—
Apr 27, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 27, 2026RFRRREFUSAL PROCESSED BY MPU—
Mar 17, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 16, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 10, 2026DOCKASSIGNED TO EXAMINER—
Feb 15, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 15, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 12, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance